My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Pfizer (NY:PFE)

26.58 -0.28 (-1.04%)

Official Closing Price Updated: 4:10 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. ↗

Today 15:05 EDT

Via Chartmill

1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever ↗

Today 5:10 EDT

This healthcare giant is trading at a discounted price today.

Via The Motley Fool

Topics Intellectual Property

2 Healthcare Stocks with Solid Fundamentals and 1 Facing Challenges

Today 0:38 EDT

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se...

Via StockStory

Starboard Value Is Betting Big on This Blue-Chip Dividend Stock. Should You?

March 12, 2026

Starboard does not have a stellar recent record, and Lamb Weston is facing its own issues. Here's what investors need to know about Lamb Weston.

Via Barchart.com

Argus Turns Bullish On Pfizer, Highlights GLP-1 And Oncology Pipeline ↗

March 05, 2026

Via Talk Markets

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...

Via Finterra

Topics Economy

The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)

March 12, 2026

Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon...

Via Finterra

Topics ETFs Intellectual Property

The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income

March 12, 2026

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start. Pfizer (PFE) has been a strong performer in 2026 and is up 9.64% so far this...

Via Barchart.com

Stay informed about the most active stocks in the S&P500 index on Wednesday's session. ↗

March 11, 2026

Via Chartmill

Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up ↗

March 10, 2026

Shares popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.

Via Investor's Business Daily

Topics Intellectual Property

2 Healthcare Stocks That Are Too Cheap to Ignore ↗

March 10, 2026

These companies' shares have fallen too far, offering investors an attractive opportunity.

Via The Motley Fool

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the...

Via MarketMinute

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering...

Via Finterra

Topics Economy Intellectual Property Lawsuit

The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)

March 10, 2026

As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗

March 10, 2026

A handful of the industry's income-generating gems are hiding in plain sight.

Via The Motley Fool

1 S&P 500 Stock with Promising Prospects and 2 We Avoid

March 10, 2026

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

Via StockStory

Topics Stocks

Looking for the most active stocks in the S&P500 index on Monday? ↗

March 09, 2026

Via Chartmill

Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable? ↗

March 09, 2026

The company incurred a loss in its most recent quarterly results.

Via The Motley Fool

Topics Intellectual Property

2 Top AI Healthcare Stocks to Buy and Hold ↗

March 09, 2026

AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

March 09, 2026

From Pfizer Inc.

Via Business Wire

Why Bristol Myers Squibb Stock Crushed it in February ↗

March 08, 2026

It delivered for shareholders in its fourth quarter of 2025 with a double beat on analyst projections.

Via The Motley Fool

Topics Intellectual Property

Where Will Eli Lilly Stock Be in 10 Years? ↗

March 07, 2026

Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

Via The Motley Fool

Topics Intellectual Property

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks ↗

March 07, 2026

Amarin is milking a cash cow, but it looks like that cow is slowly being bled to death.

Via The Motley Fool

Topics Intellectual Property

Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now ↗

March 06, 2026

Regencell Bioscience doesn't have a product yet, and there's no indication that one is on the way.

Via The Motley Fool

Tariffs News & Market Chaos ↗

March 06, 2026

President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026.

Via The Motley Fool

Topics Economy Government World Trade

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

March 06, 2026

On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a...

Via Finterra

Topics Initial Public Offering Intellectual Property

China Clears Weight-Loss Shot As Pfizer Enters Crowded Market ↗

March 06, 2026

China approves ecnoglutide weight-loss injection linked to Pfizer after trial shows up to 15.4% average weight reduction in adults.

Via Benzinga

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant...

Via MarketMinute

Topics Intellectual Property Lawsuit

Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era

March 05, 2026

Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level...

Via Finterra

Topics Intellectual Property

Forget Teva: This Dividend Top Dog Is the Real Value Buy Today ↗

March 04, 2026

Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.